Online inquiry

IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8485MR)

This product GTTS-WQ8485MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAL gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001114380.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3683
UniProt ID P20701
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8485MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13412MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ8091MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ3978MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ7873MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ7136MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ2361MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ3675MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ11985MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW